Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 1/2012

01-03-2012 | Head and Neck Cancer (T Day, Section Editor)

Well Differentiated Thyroid Carcinoma: Current Treatment

Authors: J. Kenneth Byrd, MD, Robert J. Yawn, BS, Christina S. T. Wilhoit, BA, CCRP, Nicoleta D. Sora, MD, Linda Meyers, MD, Jyotika Fernandes, MD, Terry Day, MD

Published in: Current Treatment Options in Oncology | Issue 1/2012

Login to get access

Opinion statement

Well differentiated thyroid carcinoma (WDTC) is a relatively common malignancy accounting for an estimated 37,000 thousand cases in the United States in 2009 [1]. WDTC also has a generally high 5 year survival rate that correlates with age. Papillary thyroid carcinoma (PTC) greater than 1 cm is best managed by total thyroidectomy. Thyroid lobectomy and isthmusectomy may be adequate for unifocal PTC less than 1 cm in patients without negative prognostic factors. Central compartment and possible lateral neck dissections should be performed when nodal metastases are present in the respective nodal basins. Post-operatively, radioactive iodine ablation with 131I followed by thyroid stimulating hormone (TSH) suppression is indicated in certain patients to improve locoregional control and reduce recurrence.
Literature
1.
2.
Cramer JD, et al. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registr. Surgery. 2010;148(6):1147–52. discussion 1152–3.PubMedCrossRef
3.•
Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh Q-Y, Shibru G, Bastian B, Griffin A. The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer. Ann Surg. 2007 September; 246(3): 466–471.PubMedCrossRef
4.
Boudourakis LD, et al. Evolution of the surgeon-volume, patient-outcome relationship. Ann Surg. 2009;250(1):159–65.PubMedCrossRef
5.
Hundahl SA, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer. 2000;89(1):202–17.PubMedCrossRef
6.
Flynn MB, et al. Local complications after surgical resection for thyroid carcinoma. Am J Surg. 1994;168(5):404–7.PubMedCrossRef
7.
Morton, R.P., P. Whitfield, and S. Al-Ali, Anatomical and surgical considerations of the external branch of the superior laryngeal nerve: a systematic review. Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2006. 31(5): p. 368–74.
8.
Pagedar NA, Freeman JL. Identification of the external branch of the superior laryngeal nerve during thyroidectomy. Arch Otolaryngol Head Neck Surg. 2009;135(4):360–2.PubMedCrossRef
9.
Sabour S, Manders E, Steward DL. The role of rapid PACU parathyroid hormone in reducing post-thyroidectomy hypocalcemia. Otolaryngol Head Neck Surg: Off J Am Acad of Otolaryngol Head Neck Surg. 2009;141(6):727–9.CrossRef
10.
Bilimoria KY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246(3):375–81. discussion 381-4.PubMedCrossRef
11.
Jonklaas J, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid: Off J Am Thyroid Assoc. 2006;16(12):1229–42.CrossRef
12.
Baudin E, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998;83(3):553–9.PubMedCrossRef
13.
Thyroid Carcinoma. NCCN Clinical Practice Guidelines in Oncology 2011 [cited 2011; 3.2011]Available from: www.​nccn.​org.
14.
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–28.PubMedCrossRef
15.
Carty SE, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid: Off J Am Thyroid Assoc. 2009;19(11):1153–8.CrossRef
16.
Shaha, A.R., Controversies about the central compartment in thyroid cancer. Editorial regarding the article “Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases” by Alexandre Bozec et al. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies, 2011. 268(8): p. 1097–9.
17.
Zetoune T, et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol. 2010;17(12):3287–93.PubMedCrossRef
18.
Ecker T, et al. Hemostasis in thyroid surgery: harmonic scalpel versus other techniques--a meta-analysis. Otolaryngol Head Neck Surg: Off J Am Acad Otolaryngol Head Neck Surg. 2010;143(1):17–25.CrossRef
19.
Higgins TS, et al. Recurrent laryngeal nerve monitoring versus identification alone on post-thyroidectomy true vocal fold palsy: a meta-analysis. Laryngoscope. 2011;121(5):1009–17.PubMedCrossRef
20.
Samraj, K. and K.S. Gurusamy, Wound drains following thyroid surgery. Cochrane database of systematic reviews, 2007(4): p. CD006099.
21.
Miccoli P, et al. Minimally invasive surgery for thyroid small nodules: Preliminary report. J Endocrinol Invest. 1999;22:849–51.PubMed
22.
Miccoli P, et al. Video-assisted thyroidectomy: indications and results. Langenbecks Arch Surg. 2006;391:68–71.PubMedCrossRef
23.
Sgourakis G, et al. Comparison between minimally invasive video-assisted thyroidectomy and conventional thyroidectomy: is there any evidence-based information? Thyroid: Off J Am Thyroid Assoc. 2008;18(7):721–7.CrossRef
24.
Byrd JK, et al. Minimally invasive video-assisted thyroidectomy versus conventional thyroidectomy: a cost-effective analysis. Otolaryngol Head Neck Surg: Off J Am Acad Otolaryngol Head Neck Surg. 2010;143(6):789–94.CrossRef
25.
Kuppersmith RB, Holsinger FC. Robotic thyroid surgery: an initial experience with North American patients. Laryngoscope. 2011;121(3):521–6.PubMedCrossRef
26.
Tae, K., et al., Early surgical outcomes of robotic thyroidectomy by a gasless unilateral axillo-breast or axillary approach for papillary thyroid carcinoma: 2 years’ experience. Head & Neck, 2011.
27.
Terris DJ, Singer MC, Seybt MW. Robotic facelift thyroidectomy: patient selection and technical considerations. Surg Laparosc Endosc Percutan Tech. 2011;21(4):237–42.PubMedCrossRef
28.
Wilhelm T, Metzig A. Endoscopic minimally invasive thyroidectomy (eMIT): a prospective proof-of-concept study in humans. World J Surg. 2011;35(3):543–51.PubMedCrossRef
29.
DeGroot LJ, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71(2):414–24.PubMedCrossRef
30.
Sawka AM, et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89(8):3668–76.PubMedCrossRef
31.••
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., Sherman, S. I., Steward, D. L. & Tuttle, R. M. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214. doi:10.1089/thy.2009.0110.PubMedCrossRef
32.
Jukkola A, et al. Prognostic Factors in Differentiated Thyroid Carcinomas and Their Implications for Current Staging Classifications. Endocr Relat Cancer. 2004;11:571–9.PubMedCrossRef
33.
Meier D, et al. Procedure guideline for Therapy of Thyroid Disease with 131Iodine. J Nucl Med. 2002;43(6):856–61.PubMed
34.
Robbins RJ, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med: Off Publ, Soc Nucl Med. 2002;43(11):1482–8.
35.
Tala H, et al. Five-Year Survival is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH. J Clin Endocrinol. 2011;96(7):2105–11.CrossRef
36.
Sisson JC, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine (1)(3)(1)i: practice recommendations of the american thyroid association. Thyroid: Off J Am Thyroid Assoc. 2011;21(4):335–46.CrossRef
37.
Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Cancer Netw: JNCCN. 2010;8(11):1277–86. quiz 1287.
38.
Perez CA, Santos ES, Arango BA, Raez LE, Cohen EW. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck Epub ahead of print doi: 10.​1002/​hed.​21755 2011.
39.
Monchik, et al. Radiofrequency Ablation and Percutaneous Ethanol Injection Treatment for Recurrent Local and Distant Well-Differentiated Thyroid Carcinoma. Ann Surg. 2006;244(2):296–304.PubMedCrossRef
40.
41.
Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D’Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–52. doi:10.​1056/​NEJM199411103311​901.PubMedCrossRef
42.
Fazio S, Biondi B, Carella C, Sabatini D, Cittadini A, Panza N, Lombardi G, Sacca L. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade. J Clin Endocrinol Metab. 1995;80:2222–6.PubMedCrossRef
43.
Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001;134:561–8.PubMed
44.
Kloos RT. Papillary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol. 2005;6:323–38.PubMedCrossRef
45.•
46.
Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433–41.PubMedCrossRef
Metadata
Title
Well Differentiated Thyroid Carcinoma: Current Treatment
Authors
J. Kenneth Byrd, MD
Robert J. Yawn, BS
Christina S. T. Wilhoit, BA, CCRP
Nicoleta D. Sora, MD
Linda Meyers, MD
Jyotika Fernandes, MD
Terry Day, MD
Publication date
01-03-2012
Publisher
Current Science Inc.
Published in
Current Treatment Options in Oncology / Issue 1/2012
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-011-0173-1

Other articles of this Issue 1/2012

Current Treatment Options in Oncology 1/2012 Go to the issue

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Extent of Surgery for Papillary Thyroid Cancer: Preoperative Imaging and Role of Prophylactic and Therapeutic Neck Dissection

Head and Neck Cancer (T Day, Section Editor)

mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma

Lymphomas (L Gordon, Section Editor)

Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Parathyroid Carcinoma: Update and Guidelines for Management

Head and Neck Cancer (T Day, Section Editor)

Current Treatment Options for Metastatic Head and Neck Cancer

Lymphomas (L Gordon, Section Editor)

Cutaneous T-Cell Lymphomas: A Review of New Discoveries and Treatments
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits